By Admin
Here is a telling report from the left wind New York Times actually accurately reporting a crisis we face with infectious diseases. For many reasons outlined, companies that develop antibiotics simply aren’t making it. The reasons are many. I’ll outline a few.
New drug development is extremely costly due to regulatory requirements. A new antibiotic course of therapy might cost $2000 compared to a few dollars per pill of older drugs.
Doctors are (at last) more reluctant to …read more
Source: Health Impact News
- Rating:
- Views:198 views
- Categories: Health
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr